All In Biotech

NDA 022187 · Janssen R and D

Intelence

Etravirine · Oral · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

NovelAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Jul 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jan 18, 2008

Approved uses

5

Original approval plus efficacy supplements

Registered trials

73

20 Phase 3, 0 recruiting

FAERS reports

4,438

3,903 serious, 475 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 2, 2025.

Etravirine, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see Microbiology (12.4) and Clinical Studies (14) ] . Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 2 years of age and older. ( 1 )

Mechanism: Etravirine is an antiretroviral drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • INTELENCE · ETRAVIRINE 200MG · TABLET, ORAL · Prescription · TE AB
  • INTELENCE · ETRAVIRINE 25MG · TABLET, ORAL · Prescription
  • INTELENCE · ETRAVIRINE 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Etravirine" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain286
  • drug interaction282
  • drug resistance266
  • anxiety247
  • emotional distress243
  • virologic failure237
  • anhedonia219
  • death208
  • treatment failure203
  • chronic kidney disease192
  • lipodystrophy acquired175
  • foetal exposure during pregnancy166

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200759
2008153
2009255
2010257
2011196
2012278
2013265
2014257
2015375
2016343
2017267
2018250
2019317
2020369
2021222
2022231
2023158
202493
202545
202648

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Apr 28, 2026

    Etravirine, Tablet, 100 mg (NDC 10147-0570-1). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Apr 28, 2026

    Intelence, Tablet, 100 mg (NDC 59676-570-01). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Intelence (Etravirine)

2024 spending

$2.5M

Beneficiaries

281

1,596 claims

Per beneficiary

$8,809

$22.63 per unit

View as table
YearSpending
2020$68,238,317
2021$46,936,731
2022$12,895,562
2023$4,717,541
2024$2,475,203

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 103 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.